U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C11H12N2O2S
Molecular Weight 236.29
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZILEUTON

SMILES

CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2

InChI

InChIKey=MWLSOWXNZPKENC-UHFFFAOYSA-N
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)

HIDE SMILES / InChI

Molecular Formula C11H12N2O2S
Molecular Weight 236.29
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including

Zileuton is an asthma drug that differs chemically and pharmacologically from other antiasthmatic agents. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Current data indicates that asthma is a chronic inflammatory disorder of the airways involving the production and activity of several endogenous inflammatory mediators, including leukotrienes. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, are derived from the initial unstable product of arachidonic acid metabolism, leukotriene A4 (LTA4), and can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma. Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton is marketed under the trade name ZYFLO.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZYFLO

Approved Use

ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.15 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
4.25 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
5.69 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
4.82 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.55 mg/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
7.13 mg/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.63 mg/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
7.47 mg/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4.98 μg/mL
600 mg 4 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.28 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
19.1 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
26.34 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
23.23 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
29.09 mg × h/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
28.03 mg × h/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
30.18 mg × h/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
26.51 mg × h/L
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
19.2 μg × h/mL
600 mg 4 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.85 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
2.2 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.12 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
2.34 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1.77 h
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
2.2 h
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.12 h
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
2.21 h
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.08%
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
6.98%
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.23%
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
6.7%
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.04%
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
7.01%
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.32%
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
6.73%
600 mg 4 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZILEUTON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7%
600 mg 4 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ZILEUTON plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells.
2000 Jan
Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus.
2001 Apr 15
Zileuton and atopic dermatitis.
2001 Aug
Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice.
2001 Dec
Role of the IgE-mediated system in eosinophil recruitment triggered by two consecutive cycles of sensitisation and challenge in rats.
2001 Dec
Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome.
2001 Dec
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.
2001 Jan
Efficacy of antileukotriene agents in asthma management.
2001 Jun
Discovery of leukotrienes and development of antileukotriene agents.
2001 Jun
The role of antileukotrienes in the treatment of asthma.
2001 Jun
Safety of antileukotriene agents in asthma management.
2001 Jun
Antileukotrienes in asthma: present situation.
2001 Mar
Leukotrienes play protective roles early during experimental VSV encephalitis.
2001 Nov 1
Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
2001 Oct 19
Leukotrienes in respiratory disease.
2001 Sep
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
2002
Pharmacogenetics, pharmacogenomics and airway disease.
2002
Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E.
2002 Apr
Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein.
2002 Apr 15
Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice.
2002 Aug 1
[Anti-leukotriene drugs and Churg Strauss syndrome].
2002 Feb
Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
2002 Feb
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes.
2002 Jul
Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation.
2002 Mar
Role of Ca(2+)-independent phospholipase A(2) and cyclooxygenase/lipoxygenase pathways in the nitric oxide production by murine macrophages stimulated by lipopolysaccharides.
2002 May
[New horizons in the treatment of atopic dermatitis].
2002 May-Jun
The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
2002 Oct
Interaction between nitric oxide, reactive oxygen intermediates, and peroxynitrite in the regulation of 5-lipoxygenase metabolism.
2002 Oct 10
Mediators of adenosine- and ovalbumen-induced bronchoconstriction of sensitized guinea-pig isolated airways.
2002 Sep 6
Leukotrienes, IL-13, and chemokines cooperate to induce BHR and mucus in allergic mouse lungs.
2003 Feb
The role of leukotriene inhibitors in patients with paranasal sinus disease.
2003 Jun
Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
2003 Nov
Inhibition of neutrophil leukotriene B4 production by a novel synthetic N-3 polyunsaturated fatty acid analogue, beta-oxa 21:3n-3.
2003 Nov 1
Deficiency of NADPH oxidase components p47phox and gp91phox caused granulomatous synovitis and increased connective tissue destruction in experimental arthritis models.
2003 Oct
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
2003 Sep
Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
2003 Sep
Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro.
2004 Nov
Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
2005
Leukotrienes: their role in the treatment of asthma and seasonal allergic rhinitis.
2005 Jan-Feb
5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration.
2005 Jun
Patents

Sample Use Guides

The recommended dosage of ZYFLO (Zileuton) for the symptomatic treatment of patien ts with asthma is one 600-mg tablet four times a day for a total daily dose of 2400 mg. For ease of administration, ZYFLO may be taken with meals and at bedtime.
Route of Administration: Oral
Zileuton (5 uM) inhibited LTB4 production by 99% in purified human neutrophils in the presence of fatty acid saturated albumin (fraction V).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:12:06 GMT 2025
Edited
by admin
on Mon Mar 31 18:12:06 GMT 2025
Record UNII
V1L22WVE2S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZYFLO
Preferred Name English
ZILEUTON
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-730712
Code English
(±)-1-(1-BENZO(B)THIEN-2-YLETHYL)-1-HYDROXYUREA
Systematic Name English
UREA, N-(1-BENZO(B)THIEN-2-YLETHYL)-N-HYDROXY-, (±)-
Systematic Name English
ZILEUTON [USAN]
Common Name English
NSC-759277
Code English
ZILEUTON [USP-RS]
Common Name English
zileuton [INN]
Common Name English
ZILEUTON [MI]
Common Name English
A-64077
Code English
ZILEUTON [USP MONOGRAPH]
Common Name English
ABBOTT-64077
Code English
ZILEUTON [ORANGE BOOK]
Common Name English
ZILEUTON [MART.]
Common Name English
Zileuton [WHO-DD]
Common Name English
ZILEUTON [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008683
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
NDF-RT N0000175956
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
LIVERTOX NBK548397
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
NCI_THESAURUS C1322
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
NDF-RT N0000175955
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
NDF-RT N0000008683
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
Code System Code Type Description
NSC
759277
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
DRUG BANK
DB00744
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
NSC
730712
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
ChEMBL
CHEMBL93
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
SMS_ID
100000079065
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
CHEBI
10112
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
USAN
AA-18
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
CAS
111406-87-2
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
INN
6595
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
NCI_THESAURUS
C26667
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
DAILYMED
V1L22WVE2S
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
LACTMED
Zileuton
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
MESH
C063449
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
RS_ITEM_NUM
1724656
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
WIKIPEDIA
ZILEUTON
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
PUBCHEM
60490
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
EVMPD
SUB00157MIG
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023752
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
RXCUI
40575
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY RxNorm
FDA UNII
V1L22WVE2S
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
MERCK INDEX
m11593
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY Merck Index
IUPHAR
5297
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
DRUG CENTRAL
2862
Created by admin on Mon Mar 31 18:12:06 GMT 2025 , Edited by admin on Mon Mar 31 18:12:06 GMT 2025
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
FECAL; URINE
METABOLIC ENZYME -> SUBSTRATE
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
IN-VITRO
METABOLITE -> PARENT
METABOLITE -> PARENT
IN-VITRO
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

FED CONDITION

Route of Elimination PHARMACOKINETIC